PMID- 18816482
OWN - NLM
STAT- MEDLINE
DCOM- 20090130
LR  - 20081203
IS  - 1521-2254 (Electronic)
IS  - 1099-498X (Linking)
VI  - 10
IP  - 12
DP  - 2008 Dec
TI  - Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice 
      from allergic sensitization.
PG  - 1324-33
LID - 10.1002/jgm.1256 [doi]
AB  - BACKGROUND: Currently, no treatment is available for food allergy and strict 
      avoidance of the allergenic food remains the only way to manage the allergy. New 
      strategies leading to a safe and efficacious food allergy treatment are required. 
      Modified vaccinia virus Ankara (MVA), which allows high levels of expression of 
      recombinant protein in vivo and gives rise to a Th1-biased specific immune 
      response, was used as a prophylactic vaccine in a murine model of ovalbumin (OVA) 
      allergy. METHODS: An MVA-OVA vector vaccine was prepared. Female BALB/c mice were 
      vaccinated twice with a MVA-OVA vector vaccine, followed by sensitization with 
      OVA plus alum. OVA-specific immunoglobulin E(IgE) activity was measured by 
      mediator release from rat basophilic leukaemia cells, whereas specific IgG 
      subclass titers were determined by enzyme-linked immunosorbent assay. RESULTS: 
      Expression of immunological active OVA in mammalian cells was demonstrated. 
      OVA-specific IgE levels in sera from MVA-OVA-vaccinated mice were reduced and 
      appeared delayed. The vaccine-mediated immune modulation was dose-dependent; the 
      highest vaccine dose protected 50% of the animals from allergic sensitization. 
      Upon sensitization, similar OVA-specific IgG1 titers were found in all mice, but 
      the OVA-specific IgG2a antibody levels were strongly increased in 
      MVA-OVA-vaccinated mice, signifying a Th1-biased and, non-allergic immune 
      response. CONCLUSIONS: Prophylactic vaccination with MVA-OVA delays and in part 
      even prevents the onset of a successful allergen-specific sensitization. 
      Recombinant MVA, which fulfills the requirements for clinical application, is a 
      promising candidate vector for the development of novel approaches to 
      allergen-specific prophylactic vaccination and specific immunotherapy.
CI  - Copyright (c) 2008 John Wiley & Sons, Ltd.
FAU - Albrecht, Melanie
AU  - Albrecht M
AD  - Paul-Ehrlich-Institut, Department of Allergology, Langen, Germany.
FAU - Suezer, Yasemin
AU  - Suezer Y
FAU - Staib, Caroline
AU  - Staib C
FAU - Sutter, Gerd
AU  - Sutter G
FAU - Vieths, Stefan
AU  - Vieths S
FAU - Reese, Gerald
AU  - Reese G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Gene Med
JT  - The journal of gene medicine
JID - 9815764
RN  - 0 (Immunoglobulin G)
RN  - 0 (Vaccines)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Female
MH  - Hypersensitivity/immunology/*prevention & control
MH  - Immunoglobulin G/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/genetics/immunology
MH  - Rats
MH  - Th1 Cells/immunology
MH  - *Vaccines/administration & dosage/genetics/immunology
MH  - Vaccinia virus/*genetics
EDAT- 2008/09/26 09:00
MHDA- 2009/01/31 09:00
CRDT- 2008/09/26 09:00
PHST- 2008/09/26 09:00 [pubmed]
PHST- 2009/01/31 09:00 [medline]
PHST- 2008/09/26 09:00 [entrez]
AID - 10.1002/jgm.1256 [doi]
PST - ppublish
SO  - J Gene Med. 2008 Dec;10(12):1324-33. doi: 10.1002/jgm.1256.